规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | PARP ↓ ↑ | PARP1 ↓ ↑ | PARP2 ↓ ↑ | PARP3 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PJ34 HCl |
++
PARP, EC50: 20 nM |
99%+ | |||||||||||||||||
Rucaparib phosphate |
++++
PARP, Ki: 1.4 nM |
99%+ | |||||||||||||||||
3-Aminobenzamide |
++
PARP, IC50: <50 nM |
98% | |||||||||||||||||
AZD-2461 | ✔ | 99%+ | |||||||||||||||||
BGP-15 | ✔ | 99%+ | |||||||||||||||||
NU1025 |
+
PARP, IC50: 400 nM |
98% | |||||||||||||||||
Benzamide |
+
PARP, IC50: 3.3 μM |
98% | |||||||||||||||||
Picolinamide |
+
PARP, IC50: 95 μM |
98% | |||||||||||||||||
AG14361 |
+++
PARP1, Ki: <5 nM |
98+% | |||||||||||||||||
Iniparib | ✔ | 98% | |||||||||||||||||
Talazoparib |
++++
PARP1, IC50: 0.57 nM |
99%+ | |||||||||||||||||
NMS-P118 |
++
PARP1, Kd: 0.009 μM |
98+% | |||||||||||||||||
UPF 1069 |
+
PARP1, IC50: 8.0 μM |
++
PARP2, IC50: 0.3 μM |
98% | ||||||||||||||||
A-966492 |
++++
PARP1, EC50: 1 nM PARP1, Ki: 1 nM |
+++
PARP2, Ki: 1.5 nM |
99%+ | ||||||||||||||||
Veliparib |
++
PARP1, Ki: 5.2 nM |
+++
PARP2, Ki: 2.9 nM |
98% | ||||||||||||||||
Niraparib tosylate |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
99%+ | ||||||||||||||||
Stenoparib |
++++
PARP1, IC50: 1 nM |
++++
PARP2, IC50: 1.2 nM |
98% | ||||||||||||||||
Olaparib |
+++
PARP1, IC50: 5 nM |
++++
PARP2, IC50: 1 nM |
98% | ||||||||||||||||
Niraparib |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
98% | ||||||||||||||||
ME0328 |
+
PARP1, IC50: 6.3 μM |
+
PARP3, IC50: 0.89 μM |
99%+ | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02986100 | Solid Tumor | Phase 1 | Active, not recruiting | December 2018 | Hungary ... 展开 >> PRA Magyarország Kft. Budapest, Rottenbiller Utca 13, Hungary, 1077 收起 << |
NCT02740712 | Neoplasms | Phase 1 | Active, not recruiting | May 2019 | Poland ... 展开 >> BioVirtus Research Site Kajetany, Mokra 7, Poland, 05-830 Med Polonia Poznan, Poland, 60-693 Zachodniopomorskie Centrum Onkologii Centrum Innowacji Szczecin, Poland, 71-730 收起 << |
NCT03521037 | Neoplasms | Phase 1 | Recruiting | December 1, 2019 | Czechia ... 展开 >> Onkologicka klinika VFN a 1. LF UK Recruiting Praha, Czechia, 128 08 Contact: Milada Zemanova Pharmaceutical Research Associates CZ Recruiting Praha, Czechia, 170 00 Contact: Milada Zemanova Poland Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej Recruiting Biała Podlaska, Poland, 21-500 Contact: Piotr Centkowski Med Polonia Sp. z o.o. Recruiting Poznań, Poland, 60-693 Contact: Rodryg Ramlau Zachodniopomorskie Centrum Onkologii w Szczecinie Recruiting Szczecin, Poland, 71-730 Contact: Dorota Nowak BioVirtus Centrum Medyczne Recruiting Warszawa, Poland, 02-681 Contact: Monika Tomaszewska-Kiecana, MD 48 22 545.84.64 Slovakia Summit Clinical Research s.r.o. Recruiting Bratislava, Slovakia, 831 01 Contact: Miriam Drahokoupilova United Kingdom Northern Centre for Cancer Care Recruiting Newcastle Upon Tyne, United Kingdom, NE7 7DN Contact: Yvette Drew 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.80mL 0.36mL 0.18mL |
9.00mL 1.80mL 0.90mL |
18.00mL 3.60mL 1.80mL |
CAS号 | 1327258-57-0 |
分子式 | C29H34FN3O5S |
分子量 | 555.66 |
SMILES Code | O=S(C[C@@]1(C2(C)C)C(C[C@@]2([H])CC1)=O)(O)=O.O=C(NCC3)C4=CC(F)=CC5=C4C3=C(C6=CC=C(CNC)C=C6)N5 |
MDL No. | N/A |
别名 | AG014699 camsylate; PF-01367338 camsylate |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form |